TOP TEN perturbations for Q9NVH1 (Homo sapiens)
Organism: Homo sapiens
Gene: Q9NVH1
Selected probe(set): 215792_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of Q9NVH1 (215792_s_at) across 5610 perturbations tested by GENEVESTIGATOR:
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.778861Number of Samples:2 / 3
Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
LPS study 4 (shRNA cycT1) / cycT1 depletion study 2 (shRNA)
Relative Expression (log2-ratio):-2.4755611Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA cycT1) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | cycT1 depletion study 2 (shRNA) |
MONO-MAC-6 (MM6) cells were transduced with shRNA against cyclin T1 and then mock treated. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.3394928Number of Samples:2 / 2
Experimental | LPS study 4 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-2.2064Number of Samples:2 / 2
Experimental | LPS study 4 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):2.0367317Number of Samples:3 / 3
Experimental | glioma study 17 (glioblastoma; A2B5+) |
Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
adrenal gland cancer study 4 / normal adrenal cortex tissue
Relative Expression (log2-ratio):-1.8370523Number of Samples:43 / 4
Experimental | adrenal gland cancer study 4 |
Primary tumor tissue samples of the adrenal cortex from patients with adrenocortical carcinoma (ACC). | |
Control | normal adrenal cortex tissue |
Histological normal adrenal gland cortical tissue samples derived after autopsy. |
lactic acid study 1 (hypoxia) / untreated breast epithelial cell sample
Relative Expression (log2-ratio):-1.7671967Number of Samples:3 / 3
Experimental | lactic acid study 1 (hypoxia) |
Breast epithelial cells exposed to 25mM lactic acid of pH6.7 and 2% hypoxia. ATC code: | |
Control | untreated breast epithelial cell sample |
Breast epithelial cells in control media under normoxia. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-1.4528589Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
systemic lupus erythematosus study 13 (untreated) / normal PBMC sample
Relative Expression (log2-ratio):1.4183264Number of Samples:4 / 5
Experimental | systemic lupus erythematosus study 13 (untreated) |
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists. | |
Control | normal PBMC sample |
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. |
kidney transplantation study 9 (late) / normal kidney transplant
Relative Expression (log2-ratio):-1.4007387Number of Samples:2 / 13
Experimental | kidney transplantation study 9 (late) |
Human renal allograft biopsies from deceased donors obtained 24 months after transplantation. | |
Control | normal kidney transplant |
Human renal allograft biopsies from deceased donors obtained at implantation prior to revascularization. |